The diverse spectrum of benefits on HF, arrhythmia, atherosclerotic risk and kidney disease progression also underscores the systemic actions of finerenone in attenuating the adverse multi-organ effects of mineralocorticoid receptor overactivation5. This evidence concerns the gene NR3C2 and hydrops fetalis.